Key Disease Mechanisms Linked to Amyotrophic Lateral Sclerosis in Spinal Cord Motor Neurons

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no modifying treatments available. The molecular mechanisms underpinning disease pathogenesis are not fully understood. Recent studies have employed co-expression networks to identify key genes, known as “switch genes”, responsible for dramatic transcriptional changes in the blood of ALS patients. In this study, we directly investigate the root cause of ALS by examining the changes in gene expression in motor neurons that degenerate in patients. Co-expression networks identified in ALS patients’ spinal cord motor neurons revealed 610 switch genes in seven independent microarrays. Switch genes were enriched in several pathways, including viral carcinogenesis, PI3K-Akt, focal adhesion, proteoglycans in cancer, colorectal cancer, and thyroid hormone signaling. Transcription factors ELK1 and GATA2 were identified as key master regulators of the switch genes. Protein-chemical network analysis identified valproic acid, cyclosporine, estradiol, acetaminophen, quercetin, and carbamazepine as potential therapeutics for ALS. Furthermore, the chemical analysis identified metals and organic compounds including, arsenic, copper, nickel, and benzo(a)pyrene as possible mediators of neurodegeneration. The identification of switch genes provides insights into previously unknown biological pathways associated with ALS.

[1]  Yong-jie Wei,et al.  Risk of neurodegeneration among residents of electronic waste recycling areas. , 2021, Ecotoxicology and environmental safety.

[2]  A. Soricelli,et al.  Machine Learning and Bioinformatics Framework Integration to Potential Familial DCM-Related Markers Discovery , 2021, Genes.

[3]  L. Wong,et al.  Epigenetics Modifications in Large-Artery Atherosclerosis: A Systematic Review. , 2021, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[4]  J. Matías‐Guiu,et al.  A Transcriptomic Meta-Analysis Shows Lipid Metabolism Dysregulation as an Early Pathological Mechanism in the Spinal Cord of SOD1 Mice , 2021, International journal of molecular sciences.

[5]  Shi-Yan Ng,et al.  TDP-43 mediates SREBF2-regulated gene expression required for oligodendrocyte myelination , 2021, The Journal of cell biology.

[6]  Hui Zhou,et al.  Benzo(a)pyrene exposure in utero exacerbates Parkinson's Disease (PD)-like α-synucleinopathy in A53T human alpha-synuclein transgenic mice. , 2021, Toxicology and applied pharmacology.

[7]  Jose A. Santiago,et al.  Network Analysis Identifies Sex-Specific Gene Expression Changes in Blood of Amyotrophic Lateral Sclerosis Patients , 2021, International journal of molecular sciences.

[8]  M. Onofrj,et al.  Diabetes Mellitus and Amyotrophic Lateral Sclerosis: A Systematic Review , 2021, Biomolecules.

[9]  J. W. Joo,et al.  An Integrative Transcriptome-Wide Analysis of Amyotrophic Lateral Sclerosis for the Identification of Potential Genetic Markers and Drug Candidates , 2021, International journal of molecular sciences.

[10]  Baoman Li,et al.  Astrocytes in heavy metal neurotoxicity and neurodegeneration , 2021, Brain Research.

[11]  Weineng Chen,et al.  Key Molecules and Pathways Underlying Sporadic Amyotrophic Lateral Sclerosis: Integrated Analysis on Gene Expression Profiles of Motor Neurons , 2020, Frontiers in Genetics.

[12]  P. Ungprasert,et al.  Diabetes mellitus is associated with a lower risk of amyotrophic lateral sclerosis: A systematic review and meta-analysis , 2020, Clinical Neurology and Neurosurgery.

[13]  N. Wray,et al.  Cardiovascular disease, psychiatric diagnosis and sex differences in the multistep hypothesis of amyotrophic lateral sclerosis , 2020, European journal of neurology.

[14]  M. Chang,et al.  The effectiveness of nonsteroidal anti-inflammatory drugs and acetaminophen in reduce the risk of amyotrophic lateral sclerosis? A meta-analysis , 2020, Scientific Reports.

[15]  J. Sterneckert,et al.  Genome Wide Analysis Points towards Subtype-Specific Diseases in Different Genetic Forms of Amyotrophic Lateral Sclerosis , 2020, International journal of molecular sciences.

[16]  Yinxi Wang,et al.  Benzo(a)pyrene exposure induced neuronal loss, plaque deposition, and cognitive decline in APP/PS1 mice , 2020, Journal of Neuroinflammation.

[17]  Ashwini Kumar,et al.  Minutes of PPAR-γ agonism and neuroprotection , 2020, Neurochemistry International.

[18]  Shijie Jin,et al.  Elevated exosomal secretion of miR-124-3p from spinal neurons positively associates with disease severity in ALS , 2020, Experimental Neurology.

[19]  E. D’Amico,et al.  CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset. , 2020, Environmental research.

[20]  Jose A. Santiago,et al.  Bioinformatic Analysis Reveals Phosphodiesterase 4D-Interacting Protein as a Key Frontal Cortex Dementia Switch Gene , 2020, International journal of molecular sciences.

[21]  S. Deep,et al.  Quercetin and baicalein act as a potent anti-amyloidogenic and fibril destabilizing agents for SOD1 fibrils. , 2020, ACS chemical neuroscience.

[22]  M. Turner,et al.  Identification of a potential non-coding RNA biomarker signature for amyotrophic lateral sclerosis , 2020, Brain communications.

[23]  A. Rodal,et al.  TDP-43 dysfunction restricts dendritic complexity by inhibiting CREB activation and altering gene expression , 2019, Proceedings of the National Academy of Sciences.

[24]  Phillip A. Richmond,et al.  JASPAR 2020: update of the open-access database of transcription factor binding profiles , 2019, Nucleic Acids Res..

[25]  Julian M. W. Quinn,et al.  Identification of molecular signatures and pathways to identify novel therapeutic targets in Alzheimer's disease: Insights from a systems biomedicine perspective. , 2020, Genomics.

[26]  Carbamazepine , 2019, Reactions Weekly.

[27]  E. Fraenkel,et al.  Early epigenomic and transcriptional changes reveal Elk-1 transcription factor as a therapeutic target in Huntington’s disease , 2019, Proceedings of the National Academy of Sciences.

[28]  Jose A. Santiago,et al.  Computational identification of key genes that may regulate gene expression reprogramming in Alzheimer’s patients , 2019, PloS one.

[29]  Ching-On Wong,et al.  Motor neurons from ALS patients with mutations in C9ORF72 and SOD1 exhibit distinct transcriptional landscapes. , 2019, Human molecular genetics.

[30]  Chen Peng,et al.  Epigenome-Wide Association Study Indicates Hypomethylation of MTRNR2L8 in Large-Artery Atherosclerosis Stroke. , 2019, Stroke.

[31]  Othman Soufan,et al.  NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis , 2019, Nucleic Acids Res..

[32]  Mohammad Ali Moni,et al.  Network-based approach to identify molecular signatures and therapeutic agents in Alzheimer's disease , 2019, Comput. Biol. Chem..

[33]  Nick C Fox,et al.  Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease , 2019, Nature Medicine.

[34]  W. Le,et al.  Repurposing carbamazepine for the treatment of amyotrophic lateral sclerosis in SOD1‐G93A mouse model , 2018, CNS neuroscience & therapeutics.

[35]  J. Fernández-Ruiz,et al.  Neuroprotective effects of the cannabigerol quinone derivative VCE‐003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis , 2018, Biochemical pharmacology.

[36]  Federica Conte,et al.  Network-Based Approaches to Explore Complex Biological Systems towards Network Medicine , 2018, Genes.

[37]  I. Simone,et al.  Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis , 2018, Front. Mol. Neurosci..

[38]  C. Serra,et al.  Disruption by SaCas9 Endonuclease of HERV-Kenv, a Retroviral Gene with Oncogenic and Neuropathogenic Potential, Inhibits Molecules Involved in Cancer and Amyotrophic Lateral Sclerosis , 2018, Viruses.

[39]  P. Andersen,et al.  Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion , 2018, Annals of neurology.

[40]  F. Zhou,et al.  Raloxifene, a promising estrogen replacement, limits TDP-25 cell death by enhancing autophagy and suppressing apoptosis , 2018, Brain Research Bulletin.

[41]  Satoshi O. Suzuki,et al.  Expression of CRYM in different rat organs during development and its decreased expression in degenerating pyramidal tracts in amyotrophic lateral sclerosis , 2018, Neuropathology : official journal of the Japanese Society of Neuropathology.

[42]  Yasuo Watanabe,et al.  Edaravone and cyclosporine A as neuroprotective agents for acute ischemic stroke , 2018, Acute medicine & surgery.

[43]  M. Alarcón,et al.  New insights into the gene expression associated to amyotrophic lateral sclerosis. , 2018, Life sciences.

[44]  A. Chiò,et al.  The role of pre‐morbid diabetes on developing amyotrophic lateral sclerosis , 2018, European journal of neurology.

[45]  Artemis G. Hatzigeorgiou,et al.  DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA–gene interactions , 2017, Nucleic Acids Res..

[46]  Hsien-Da Huang,et al.  miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions , 2017, Nucleic Acids Res..

[47]  Stephen A. Goutman,et al.  Amyotrophic lateral sclerosis , 2022, Nature Reviews Disease Primers.

[48]  Daniela A. Recabarren,et al.  Gene networks in neurodegenerative disorders. , 2017, Life sciences.

[49]  J. Kira,et al.  Differential activation of neuronal and glial STAT3 in the spinal cord of the SOD1G93A mouse model of amyotrophic lateral sclerosis , 2017, The European journal of neuroscience.

[50]  Vijay Pande,et al.  Quercitrin and quercetin 3-&bgr;-D-glucoside as chemical chaperones for the A4V SOD1 ALS-causing mutant , 2017, Protein engineering, design & selection : PEDS.

[51]  Hongquan Jiang,et al.  Downregulation of Homer1b/c in SOD1 G93A Models of ALS: A Novel Mechanism of Neuroprotective Effect of Lithium and Valproic Acid , 2016, International journal of molecular sciences.

[52]  M. Weisskopf,et al.  Cardiovascular disease and diagnosis of amyotrophic lateral sclerosis: A population based study , 2016, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[53]  R. Sharma,et al.  Quercetin attenuates neuronal death against aluminum-induced neurodegeneration in the rat hippocampus , 2016, Neuroscience.

[54]  N. Mewton,et al.  Cyclosporine A, a Potential Therapy of Ischemic Reperfusion Injury. A Common History for Heart and Brain , 2016, Cerebrovascular Diseases.

[55]  S. Schmidt,et al.  Blood levels of trace metals and amyotrophic lateral sclerosis. , 2016, Neurotoxicology.

[56]  Fabian J Theis,et al.  miTALOS v2: Analyzing Tissue Specific microRNA Function , 2016, PloS one.

[57]  Hsien-Da Huang,et al.  miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database , 2015, Nucleic Acids Res..

[58]  P. Preux,et al.  Epidemiology of amyotrophic lateral sclerosis: A review of literature. , 2016, Revue neurologique.

[59]  A. Taraszewska,et al.  Protective effect of valproic acid on cultured motor neurons under glutamate excitotoxic conditions. Ultrastructural study. , 2015, Folia neuropathologica.

[60]  Y. Bossé,et al.  Altered intestinal functions and increased local inflammation in insulin-resistant obese subjects: a gene-expression profile analysis , 2015, BMC Gastroenterology.

[61]  D. Chuang,et al.  Downregulated AEG-1 together with inhibited PI3K/Akt pathway is associated with reduced viability of motor neurons in an ALS model , 2015, Molecular and Cellular Neuroscience.

[62]  M. Ren,et al.  Notch pathway is activated in cell culture and mouse models of mutant SOD1-related familial amyotrophic lateral sclerosis, with suppression of its activation as an additional mechanism of neuroprotection for lithium and valproate , 2015, Neuroscience.

[63]  M. Weisskopf,et al.  Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Study. , 2015, JAMA neurology.

[64]  M. Rattray,et al.  C9ORF72 GGGGCC Expanded Repeats Produce Splicing Dysregulation which Correlates with Disease Severity in Amyotrophic Lateral Sclerosis , 2015, PloS one.

[65]  Xuebing Ding,et al.  Valproate Attenuates 25-kDa C-Terminal Fragment of TDP-43-Induced Neuronal Toxicity via Suppressing Endoplasmic Reticulum Stress and Activating Autophagy , 2015, International journal of biological sciences.

[66]  M. Fehlings,et al.  Riluzole as a Neuroprotective Drug for Spinal Cord Injury: From Bench to Bedside , 2015, Molecules.

[67]  Daniela C. Zarnescu,et al.  PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43. , 2015, Human molecular genetics.

[68]  F. Piehl,et al.  Risk factors for amyotrophic lateral sclerosis , 2015, Clinical epidemiology.

[69]  N. Pochet,et al.  Targeting miR‐155 restores abnormal microglia and attenuates disease in SOD1 mice , 2015, Annals of neurology.

[70]  Samira N. Kashefi,et al.  Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study , 2015, Journal of Neural Transmission.

[71]  R. Bullock,et al.  Evidence to support mitochondrial neuroprotection, in severe traumatic brain injury , 2015, Journal of Bioenergetics and Biomembranes.

[72]  Johnathan Cooper-Knock,et al.  Loss of nuclear TDP‐43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones , 2014, Neuropathology and applied neurobiology.

[73]  H. Akiyama,et al.  Distinct pathways leading to TDP-43-induced cellular dysfunctions. , 2014, Human molecular genetics.

[74]  Junling Gao,et al.  STAT3 Modulation to Enhance Motor Neuron Differentiation in Human Neural Stem Cells , 2014, PloS one.

[75]  C. Ríos,et al.  Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis , 2014, Journal of the Neurological Sciences.

[76]  Rui Huang,et al.  An exploratory study of the association between thyroid hormone and survival of amyotrophic lateral sclerosis , 2014, Neurological Sciences.

[77]  Hanfei Sun,et al.  Target analysis by integration of transcriptome and ChIP-seq data with BETA , 2013, Nature Protocols.

[78]  G. Olmos,et al.  Neuroprotective Effects of Estradiol on Motoneurons in a Model of Rat Spinal Cord Embryonic Explants , 2013, Cellular and Molecular Neurobiology.

[79]  S. Booth,et al.  Early Mechanisms of Pathobiology Are Revealed by Transcriptional Temporal Dynamics in Hippocampal CA1 Neurons of Prion Infected Mice , 2012, PLoS pathogens.

[80]  Gerry Shaw,et al.  Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[81]  A. Maggi,et al.  The Peroxisome Proliferator-activated Receptor γ (PPARγ) Controls Natural Protective Mechanisms against Lipid Peroxidation in Amyotrophic Lateral Sclerosis , 2012, The Journal of Biological Chemistry.

[82]  Samira N. Kashefi,et al.  Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study , 2012, Acta Neuropathologica.

[83]  U. Bogdahn,et al.  A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis , 2012, PloS one.

[84]  S. Rutkove,et al.  Reducing systemic hypermetabolism by inducing hypothyroidism does not prolong survival in the SOD1-G93A mouse , 2012, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[85]  A. Giralt,et al.  Activation of Elk‐1 participates as a neuroprotective compensatory mechanism in models of Huntington’s disease , 2012, Journal of neurochemistry.

[86]  Xiaozhong Peng,et al.  MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice , 2012, Neurobiology of Aging.

[87]  S. Johann,et al.  Regulation of Choline Acetyltransferase Expression by 17β‐Oestradiol in NSC‐34 Cells and in the Spinal Cord , 2011, Journal of neuroendocrinology.

[88]  Fabian J Theis,et al.  miTALOS: analyzing the tissue-specific regulation of signaling pathways by human and mouse microRNAs. , 2011, RNA.

[89]  L. Garcia-Segura,et al.  Selective estrogen receptor modulators as brain therapeutic agents. , 2011, Journal of molecular endocrinology.

[90]  B. Sharrack,et al.  Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis , 2011, Brain : a journal of neurology.

[91]  Pamela A McCombe,et al.  Effects of gender in amyotrophic lateral sclerosis. , 2010, Gender medicine.

[92]  J. Ávila Common mechanisms in neurodegeneration , 2010, Nature Medicine.

[93]  Avi Ma'ayan,et al.  ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments , 2010, Bioinform..

[94]  K. Gruis,et al.  The Association of Exposure to Lead, Mercury, and Selenium and the Development of Amyotrophic Lateral Sclerosis and the Epigenetic Implications , 2010, Neurodegenerative Diseases.

[95]  Paul G. Ince,et al.  Mutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis (ALS) , 2010, PloS one.

[96]  J. Eberwine,et al.  A Neurotoxic Phosphoform of Elk-1 Associates with Inclusions from Multiple Neurodegenerative Diseases , 2010, PloS one.

[97]  A. Hiroi,et al.  Activation of STAT3 and inhibitory effects of pioglitazone on STAT3 activity in a mouse model of SOD1‐mutated amyotrophic lateral sclerosis , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.

[98]  A. Higginbottom,et al.  Mutations in CHMP 2 B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis ( ALS ) , 2010 .

[99]  L. H. van den Berg,et al.  Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis , 2009, Annals of neurology.

[100]  A. Kakita,et al.  Activation of Signal Transducer and Activator of Transcription-3 in the Spinal Cord of Sporadic Amyotrophic Lateral Sclerosis Patients , 2009, Neurodegenerative Diseases.

[101]  A. Contestabile,et al.  Long‐term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis , 2009, Muscle & nerve.

[102]  D. Chuang,et al.  Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model , 2008, Neuroscience.

[103]  B. Gwag,et al.  Effects of estrogen on lifespan and motor functions in female hSOD1 G93A transgenic mice , 2008, Journal of the Neurological Sciences.

[104]  M. Kiaei Peroxisome Proliferator-Activated Receptor-γ in Amyotrophic Lateral Sclerosis and Huntington's Disease , 2008, PPAR research.

[105]  Robert H. Brown,et al.  Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[106]  A. Echaniz-Laguna,et al.  Sodium Valproate Exerts Neuroprotective Effects In Vivo through CREB-Binding Protein-Dependent Mechanisms But Does Not Improve Survival in an Amyotrophic Lateral Sclerosis Mouse Model , 2007, The Journal of Neuroscience.

[107]  N. Howell,et al.  Development of 17α‐Estradiol as a Neuroprotective Therapeutic Agent: Rationale and Results from a Phase I Clinical Study , 2005, Annals of the New York Academy of Sciences.

[108]  M. Beal,et al.  Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis , 2005, Experimental Neurology.

[109]  S. Sakoda,et al.  Benefit of valproic acid in suppressing disease progression of ALS model mice , 2004, The European journal of neuroscience.

[110]  L. V. D. Berg,et al.  Ovariectomy and 17beta-estradiol modulate disease progression of a mouse model of ALS. , 2004, Brain research.

[111]  W. Bradley,et al.  An ALS mouse model with a permeable blood–brain barrier benefits from systemic cyclosporine A treatment , 2004, Journal of neurochemistry.

[112]  G. Stephanopoulos,et al.  Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. , 2004, Physiological genomics.

[113]  C. Mattingly,et al.  The Comparative Toxicogenomics Database (CTD). , 2003, Environmental health perspectives.

[114]  K. Csiszȧr,et al.  Intrathecal cyclosporin prolongs survival of late-stage ALS mice , 2001, Brain Research.

[115]  S. Shimohama,et al.  Protection of cultured spinal motor neurons by estradiol , 2000, Neuroreport.

[116]  S. Heck,et al.  The female sex hormone oestrogen as neuroprotectant: activities at various levels. , 2000, Novartis Foundation symposium.

[117]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[118]  S H Appel,et al.  Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. , 1995, Brain : a journal of neurology.